Neuro-Oncology and Radiogenomics: Time to Integrate?

References

1. 1.↵
   1. Louis DN,
   2. Perry A,
   3. Reifenberger G, et al

   . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016;131:803–20 doi:10.1007/s00401-016-1545-1 pmid:27157931

   CrossRefPubMed
2. 2.↵
   1. Louis DO,
   2. Wiestler OD,
   3. Cavanee WK

   . World Health Organization Histological Classification of Tumours of the Central Nervous System. International Agency for Research on Cancer; 2016
3. 3.↵
   1. Saito T,
   2. Muragaki Y,
   3. Maruyama T, et al

   . Calcification on CT is a simple and valuable preoperative indicator of 1p/19q loss of heterozygosity in supratentorial brain tumors that are suspected grade II and III gliomas. Brain Tumor Pathol 2016;33:175–82 doi:10.1007/s10014-016-0249-5 pmid:26849373

   CrossRefPubMed
4. 4.↵
   1. Lasocki A,
   2. Gaillard F,
   3. Gorelik A, et al

   . MRI features can predict 1p/19q status in intracranial gliomas. AJNR Am J Neuroradiol 2018;39:687–92 doi:10.3174/ajnr.A5572 pmid:29519793

   Abstract/FREE Full Text
5. 5.↵
   1. Cicone F,
   2. Carideo L,
   3. Scaringi C, et al

   . (18)F-DOPA uptake does not correlate with IDH mutation status and 1p/19q co-deletion in glioma. Ann Nucl Med 2019;33:295–302 doi:10.1007/s12149-018-01328-3 pmid:30607877

   CrossRefPubMed
6. 6.↵
   1. Verger A,
   2. Metellus P,
   3. Sala Q, et al

   . IDH mutation is paradoxically associated with higher (18)F-FDOPA PET uptake in diffuse grade II and grade III gliomas. Eur J Nucl Med Mol Imaging 2017;44:1306–11 doi:10.1007/s00259-017-3668-6 pmid:28293705

   CrossRefPubMed
7. 7.↵
   1. Nakae S,
   2. Murayama K,
   3. Sasaki H, et al

   . Prediction of genetic subgroups in adult supra tentorial gliomas by pre- and intraoperative parameters. J Neurooncol 2017;131:403–12 doi:10.1007/s11060-016-2313-8 pmid:27837434

   CrossRefPubMed
8. 8.↵
   1. Dang L,
   2. White DW,
   3. Gross S, et al

   . Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462:739–44 doi:10.1038/nature08617 pmid:19935646

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Choi C,
   2. Ganji SK,
   3. DeBerardinis RJ, et al

   . 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 2012;18:624–29 doi:10.1038/nm.2682 pmid:22281806

   CrossRefPubMed
10. 10.↵
    1. Suh CH,
    2. Kim HS,
    3. Jung SC, et al

    . Imaging prediction of isocitrate dehydrogenase (IDH) mutation in patients with glioma: a systemic review and meta-analysis. Eur Radiol 2019;29:745–58 doi:10.1007/s00330-018-5608-7 pmid:30003316

    CrossRefPubMed
11. 11.↵
    1. Jiang S,
    2. Zou T,
    3. Eberhart CG, et al

    . Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI. Magn Reson Med 2017;78:1100–09 doi:10.1002/mrm.26820 pmid:28714279

    CrossRefPubMed
12. 12.↵
    1. Batchala PP,
    2. Muttikkal TJE,
    3. Donahue JH, et al

    . Neuroimaging-based classification algorithm for predicting 1p/19q-codeletion status in IDH-mutant lower grade gliomas. AJNR Am J Neuroradiol 2019;40:426–32 doi:10.3174/ajnr.A5957 pmid:30705071

    Abstract/FREE Full Text
13. 13.↵
    1. Li Z,
    2. Wang Y,
    3. Yu J, et al

    . Deep learning based radiomics (DLR) and its usage in noninvasive IDH1 prediction for low grade glioma. Sci Rep 2017;7:5467 doi:10.1038/s41598-017-05848-2 pmid:28710497

    CrossRefPubMed
14. 14.↵
    1. Gillies RJ,
    2. Kinahan PE,
    3. Hricak H

    . Radiomics: images are more than pictures, they are data. Radiology 2016;278:563–77 doi:10.1148/radiol.2015151169 pmid:26579733

    CrossRefPubMed
15. 15.↵
    1. Rudie JD,
    2. Rauschecker AM,
    3. Bryan RN, et al

    . Emerging applications of artificial intelligence in neuro-oncology. Radiology 2019;290:607–18 doi:10.1148/radiol.2018181928 pmid:30667332

    CrossRefPubMed
16. 16.↵
    1. Chang P,
    2. Grinband J,
    3. Weinberg BD, et al

    . Deep-learning convolutional neural networks accurately classify genetic mutations in gliomas. AJNR Am J Neuroradiol 2018;39:1201–07 doi:10.3174/ajnr.A5667 pmid:29748206

    Abstract/FREE Full Text
17. 17.↵
    1. Patel SH,
    2. Poisson LM,
    3. Brat DJ, et al

    . T2-FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas: a TCGA/TCIA project. Clin Cancer Res 2017;23:6078–85 doi:10.1158/1078-0432.CCR-17-0560 pmid:28751449

    Abstract/FREE Full Text
18. 18.↵
    1. Broen MPG,
    2. Smits M,
    3. Wijnenga MMJ, et al

    . The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study. Neuro-Oncol 2018;20:1393–99 doi:10.1093/neuonc/noy048 pmid:29590424

    CrossRefPubMed
19. 19.↵
    1. Johnson DR,
    2. Kaufmann TJ,
    3. Patel SH, et al

    . There is an exception to every rule-T2-FLAIR mismatch sign in gliomas. Neuroradiology 2019;61:225–27 doi:10.1007/s00234-018-2148-4 pmid:30565056

    CrossRefPubMed
20. 20.↵
    1. Juratli TA,
    2. Tummala SS,
    3. Riedl A, et al

    . Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups. J Neurooncol 2019;141:327–35 doi:10.1007/s11060-018-03034-6 pmid:30536195

    CrossRefPubMed
21. 21.↵
    1. Schiff D,
    2. van den Bent M,
    3. Vogelbaum MA, et al

    . Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus. Neuro Oncol 2019;21:837–53 doi:10.1093/neuonc/noz033

    CrossRefPubMed
22. 22.↵
    1. Weller M,
    2. van den Bent M,
    3. Hopkins K

    , European Association for Neuro-Oncology (EANO) Task Force on Malignant Glioma, et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 2014;15:e395–403 doi:10.1016/S1470-2045(14)70011-7 pmid:25079102

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Li YM,
    2. Suki D,
    3. Hess K, et al

    . The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection? J Neurosurg 2016;124:977–88 doi:10.3171/2015.5.JNS142087 pmid:26495941

    CrossRefPubMed
24. 24.↵
    1. Pessina F,
    2. Navarria P,
    3. Cozzi L, et al

    . Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience. J Neurooncol 2017;135:129–39 doi:10.1007/s11060-017-2559-9 pmid:28689368

    CrossRefPubMed
25. 25.↵
    1. Lasocki A,
    2. Gaillard F

    . Non-contrast-enhancing tumor: a new frontier in glioblastoma research. AJNR Am J Neuroradiol 2019;40:758–65 doi:10.3174/ajnr.A6025 pmid:30948373

    Abstract/FREE Full Text
26. 26.↵
    1. Duffau H

    . Diffuse low-grade glioma, oncological outcome and quality of life: a surgical perspective. Curr Opin Oncol 2018;30:383–89 doi:10.1097/CCO.0000000000000483 pmid:30124519

    CrossRefPubMed
27. 27.↵
    1. Beh SMJ,
    2. Cook MJ,
    3. D’Souza WJ

    . Isolated amygdala enlargement in temporal lobe epilepsy: a systematic review. Epilepsy Behav 2016;60:33–41 doi:10.1016/j.yebeh.2016.04.015 pmid:27176882

    CrossRefPubMed
28. 28.↵
    1. Graus F,
    2. Titulaer MJ,
    3. Balu R, et al

    . A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016;15:391–404 doi:10.1016/S1474-4422(15)00401-9 pmid:26906964

    CrossRefPubMed
29. 29.↵
    1. Thust SC,
    2. Hassanein S,
    3. Bisdas S, et al

    . Apparent diffusion coefficient for molecular subtyping of non-gadolinium-enhancing WHO grade II/III glioma: volumetric segmentation versus two-dimensional region of interest analysis. Eur Radiol 2018;28:3779–88 doi:10.1007/s00330-018-5351-0 pmid:29572636

    CrossRefPubMed
30. 30.↵
    1. Chen H,
    2. Judkins J,
    3. Thomas C, et al

    . Mutant IDH1 and seizures in patients with glioma. Neurology 2017;88:1805–13 doi:10.1212/WNL.0000000000003911 pmid:28404805

    Abstract/FREE Full Text
31. 31.↵
    1. Neal A,
    2. Kwan P,
    3. O’Brien TJ, et al

    . IDH1 and IDH2 mutations in postoperative diffuse glioma-associated epilepsy. Epilepsy Behav 2018;78:30–36 doi:10.1016/j.yebeh.2017.10.027 pmid:29172136

    CrossRefPubMed
32. 32.↵
    1. Neal A,
    2. Morokoff A,
    3. O'Brien TJ, et al

    . Postoperative seizure control in patients with tumor-associated epilepsy. Epilepsia 2016;57:1779–88 doi:10.1111/epi.13562 pmid:27666131

    CrossRefPubMed
33. 33.↵
    1. Liubinas SV,
    2. D'Abaco GM,
    3. Moffat BM, et al

    . IDH1 mutation is associated with seizures and protoplasmic subtype in patients with low-grade gliomas. Epilepsia 2014;55:1438–43 doi:10.1111/epi.12662 pmid:24903073

    CrossRefPubMed
34. 34.↵
    1. Horbinski C

    . What do we know about IDH1/2 mutations so far, and how do we use it? Acta Neuropathol 2013;125:621–36 doi:10.1007/s00401-013-1106-9 pmid:23512379

    CrossRefPubMedWeb of Science
35. 35.↵
    1. Louis DN,
    2. Wesseling P,
    3. Paulus W, et al

    . cIMPACT-NOW update 1: not otherwise specified (NOS) and not elsewhere classified (NEC). Acta Neuropathol 2018;135:481–84 doi:10.1007/s00401-018-1808-0 pmid:29372318

    CrossRefPubMed
36. 36.↵
    1. Chen L,
    2. Voronovich Z,
    3. Clark K, et al

    . Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma. Neuro Oncol 2014;16:1478–83 doi:10.1093/neuonc/nou097 pmid:24860178

    CrossRefPubMed
37. 37.↵
    1. Lasocki A,
    2. Tsui A,
    3. Gaillard F, et al

    . Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma. J Clin Neurosci 2017;39:170–75 doi:10.1016/j.jocn.2017.01.007 pmid:28214089

    CrossRefPubMed
38. 38.↵
    1. Weller M,
    2. van den Bent M,
    3. Tonn JC, et al

    . European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol 2017;18:e315–29 doi:10.1016/S1470-2045(17)30194-8 pmid:28483413

    CrossRefPubMed
39. 39.↵
    1. Rogers TW,
    2. Toor G,
    3. Drummond K, et al

    . The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas. J Neurooncol 2018;137:181–89 doi:10.1007/s11060-017-2710-7 pmid:29218432

    CrossRefPubMed
40. 40.↵
    1. Louis DN,
    2. Aldape K,
    3. Brat DJ, et al

    . Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. Acta Neuropathol 2017;133:1–3 doi:10.1007/s00401-016-1646-x pmid:27909809

    CrossRefPubMed
41. 41.↵
    1. Louis DN,
    2. Wiestler OD,
    3. Cavanee WK

    . World Health Organization histological classification of tumours of the central nervous system. International Agency for Research on Cancer, Lyon; 2007
42. 42.↵
    1. Louis DN,
    2. Giannini C,
    3. Capper D, et al

    . cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol 2018;135:639–42 doi:10.1007/s00401-018-1826-y pmid:29497819

    CrossRefPubMed
43. 43.↵
    1. Brat DJ,
    2. Aldape K,
    3. Colman H, et al

    . cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV.” Acta Neuropathol 2018;136:805–10 doi:10.1007/s00401-018-1913-0 pmid:30259105

    CrossRefPubMed
44. 44.↵
    1. Horbinski C,
    2. Nikiforova MN,
    3. Hobbs J, et al

    . The importance of 10q status in an outcomes-based comparison between 1p/19q fluorescence in situ hybridization and polymerase chain reaction-based microsatellite loss of heterozygosity analysis of oligodendrogliomas. J Neuropathol Exp Neurol 2012;71:73–82 doi:10.1097/NEN.0b013e318240fa65 pmid:22157622

    CrossRefPubMed
45. 45.↵
    1. Lasocki A,
    2. Tsui A,
    3. Tacey MA, et al

    . MRI grading versus histology: predicting survival of World Health Organization grade II–IV astrocytomas. AJNR Am J Neuroradiol 2015;36:77–83 doi:10.3174/ajnr.A4077 pmid:25104288

    Abstract/FREE Full Text
46. 46.↵
    1. Preusser M,
    2. Wohrer A,
    3. Stary S, et al

    . Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens. J Neuropathol Exp Neurol 2011;70:715–23 doi:10.1097/NEN.0b013e31822713f0 pmid:21760534

    CrossRefPubMed
47. 47.↵
    1. Walker EJ,
    2. Zhang C,
    3. Castelo-Branco P, et al

    . Monoallelic expression determines oncogenic progression and outcome in benign and malignant brain tumors. Cancer Res 2012;72:636–44 doi:10.1158/0008-5472.CAN-11-2266 pmid:22144470

    Abstract/FREE Full Text
48. 48.↵
    1. Pusch S,
    2. Sahm F,
    3. Meyer J, et al

    . Glioma IDH1 mutation patterns off the beaten track. Neuropathol Appl Neurobiol 2011;37:428–30 doi:10.1111/j.1365-2990.2010.01127.x pmid:20874727

    CrossRefPubMed
49. 49.↵
    1. Jin G,
    2. Reitman ZJ,
    3. Duncan CG, et al

    . Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. Cancer Res 2013;73:496–501 doi:10.1158/0008-5472.CAN-12-2852 pmid:23204232

    Abstract/FREE Full Text
50. 50.↵
    1. Tietze A,
    2. Choi C,
    3. Mickey B, et al

    . Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting. J Neurosurg 2018;128:391–98 doi:10.3171/2016.10.JNS161793 pmid:28298040

    CrossRefPubMed
51. 51.↵
    1. Huse JT,
    2. Diamond EL,
    3. Wang L, et al

    . Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true “oligoastrocytoma”? Acta Neuropathol 2015;129:151–53 doi:10.1007/s00401-014-1359-y pmid:25359109

    CrossRefPubMed
52. 52.↵
    1. Wilcox P,
    2. Li CC,
    3. Lee M, et al

    . Oligoastrocytomas: throwing the baby out with the bathwater? Acta Neuropathol 2015;129:147–49 doi:10.1007/s00401-014-1353-4 pmid:25304041

    CrossRefPubMed
53. 53.↵
    1. Huang J,
    2. Yu J,
    3. Tu L, et al

    . Isocitrate dehydrogenase mutations in glioma: from basic discovery to therapeutics development. Front Oncol 2019;9:506 doi:10.3389/fonc.2019.00506 pmid:31263678

    CrossRefPubMed
54. 54.↵
    1. Carrillo JA,
    2. Lai A,
    3. Nghiemphu PL, et al

    . Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol 2012;33:1349–55 doi:10.3174/ajnr.A2950 pmid:22322613

    Abstract/FREE Full Text
55. 55.↵
    1. Lasocki A,
    2. Gaillard F,
    3. Tacey M, et al

    . Morphologic patterns of noncontrast-enhancing tumor in glioblastoma correlate with IDH1 mutation status and patient survival. J Clin Neurosci 2018;47:168–73 doi:10.1016/j.jocn.2017.09.007 pmid:28988652

    CrossRefPubMed
56. 56.↵
    1. Price SJ,
    2. Allinson K,
    3. Liu H, et al

    . Less invasive phenotype found in isocitrate dehydrogenase-mutated glioblastomas than in isocitrate dehydrogenase wild-type glioblastomas: a diffusion-tensor imaging study. Radiology 2017;283:215–21 doi:10.1148/radiol.2016152679 pmid:27849434

    CrossRefPubMed
57. 57.↵
    1. Ramos P,
    2. Bentires-Alj M

    . Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. Oncogene 2015;34:3617–26 doi:10.1038/onc.2014.314 pmid:25263438

    CrossRefPubMed
58. 58.↵
    1. Leu K,
    2. Ott GA,
    3. Lai A, et al

    . Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas. J Neurooncol 2017;134:177–88 doi:10.1007/s11060-017-2506-9 pmid:28547590

    CrossRefPubMed
59. 59.↵
    1. Xing Z,
    2. Yang X,
    3. She D, et al

    . Noninvasive assessment of IDH mutational status in World Health Organization grade II and III astrocytomas using DWI and DSC-PWI combined with conventional MR imaging. AJNR Am J Neuroradiol 2017;38:1138–44 doi:10.3174/ajnr.A5171 pmid:28450436

    Abstract/FREE Full Text
60. 60.↵
    1. Darlix A,
    2. Deverdun J,
    3. Menjot de Champfleur N, et al

    . IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas. J Neurooncol 2017;133:37–45 doi:10.1007/s11060-017-2421-0 pmid:28434111

    CrossRefPubMed